DPP-4 inhibitors × glycemic control

TrialDiabetes, obesity & metabolism2014

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.

V Lukashevich et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 318 people · 2014

No range given

Reported lower glycemic control, no range given

−0.76percentage points

As reported

difference −0.76 %, no interval

No range given

Reported lower glycemic control, no range given

−1.13mmol/l

As reported

difference −1.13 mmol/l, no interval

No range given

Reported lower glycemic control, no range given

−0.97percentage points

As reported

difference −0.97 %, no interval

Three numbers in the abstract

the abstract, start to end

with a between-treatment difference of -0.76% (p < 0.001).

between vildagliptin and placebo was -1.13 mmol/l (p < 0.001).

7.82% (between-treatment difference: -0.97%; p < 0.001) with significantly

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−0.76
Glycemic control
−1.13
Glycemic control
−0.97
DPP-4 inhibitorsGlycemic control

DPP-4 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.820.82 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

33 papers cite it

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 24199686